Home Journals Articles Updates About
CN
image
收藏切换
Tumor-homing peptide-based NIR-II probes for targeted spontaneous breast tumor imaging
收藏切换
PDF
Hui Zhoua, b, 1, Shanshan Lib, 1, Xiaodong Zengb, Mengxian Zhangb, Lin Tangb, Qianqian Lib, Deliang Chend, *, Xianli Menga, **, Xuechuan Honga, b, c, **
Chinese Chemical Letters | 2020, 31(6) : 1382 - 1386
Less
收藏切换
Chinese Chemical Letters | 2020, 31(6): 1382-1386
• Communication •
Tumor-homing peptide-based NIR-II probes for targeted spontaneous breast tumor imaging
Full
Hui Zhoua, b, 1, Shanshan Lib, 1, Xiaodong Zengb, Mengxian Zhangb, Lin Tangb, Qianqian Lib, Deliang Chend, *, Xianli Menga, **, Xuechuan Honga, b, c, **
Affiliations
  • a Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
  • b Key Laboratory of Combinatorial Biosynthesis and Drug Discovery(MOE), Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Shenzhen Institute of Wuhan University, Shenzhen 518057, China
  • c College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lasa 850000, China
  • d Jiangxi Key Laboratory of Organo-Pharmaceutical Chemistry, Chemistry and Chemical Engineering College, Gannan Normal University, Ganzhou 341000, China
Published: 2020-06-15 doi: 10.1016/j.cclet.2020.04.030
Outline
收藏切换

Fluorescence imaging in the second near-infrared window (NIR-II, 1000-1700 nm) is a promising modality for real-time imaging of cancer and image-guided surgery with superior in vivo optical properties. So far, very few NIR-II fluorophores have been reported for in vivo biomedical imaging of chemically-induced spontaneous breast carcinoma. Herein, a NIR-II fluorescent probe CH1055-F3 with the nucleolin-targeted tumor-homing peptide F3 was demonstrated to preferentially accumulate in 4T1 tumors. More importantly, CH1055-F3 exhibited specific NIR-II signals with high spatial and temporal resolution, strong tumor uptake, and remarkable NIR-II image-guided surgery in dimethylbenzan-thracene (DMBA)-induced spontaneous breast tumor rats. This report presents the first tumor-homing peptide-based NIR-II probe to diagnose transplantable and spontaneous breast tumors by the active targeting.

NIR-II imaging  /  F3 peptide  /  Image-guided surgery  /  Spontaneous breast carcinoma  /  NIR-II probes
Hui Zhou, Shanshan Li, Xiaodong Zeng, Mengxian Zhang, Lin Tang, Qianqian Li, Deliang Chen, Xianli Meng, Xuechuan Hong. Tumor-homing peptide-based NIR-II probes for targeted spontaneous breast tumor imaging[J]. Chinese Chemical Letters, 2020 , 31 (6) : 1382 -1386 . DOI: 10.1016/j.cclet.2020.04.030
Full Text
Less
Breast cancer is one of the most common malignant cancers among women in the world, which affects countries at all levels of modernization [1-3]. It accounts for ~30% of new cases and is the second leading cause of cancer deaths in females [4]. Medical imaging such as computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET) has intensively used in all phases of breast cancer detection, therapy monitoring and post-therapeutic follow-up. However, current clinical imaging techniques have some limitations for studying in vivo biological changes in relation with diagnosis, carcinogenesis, therapy response and prognosis [5]. In vivo fluorescence imaging in the first near-infrared window (700-900 nm, NIR-I), such as indocyanine green (ICG), has been widely used for early diagnosis and image-guided sentinel lymph node biopsy of breast cancer in clinic over the last decade [6-10]. Recently, NIR-II fluorescence imaging (1000-1700 nm) has achieved a higher tumor-to-normal tissue ratio, excellent temporal and spatial resolutions, deeper imaging depths, and opened up a new era for small molecular imaging [11, 12]. Particularly, NIR-IIb sub-window (1500-1700 nm) shows tremendous benefits of negligible scattering, near-zero auto-fluorescence, and unparalleled tissue-imaging depths on in vivo fluorescence bioimaging [13-16]. So far, numerous inorganic and organic NIR-II, NIR-IIa (1300-1400 nm) and NIR-IIb probes, such as quantum dots (QDs) [17-21], single-walled carbon nanotubes (SWNTs) [22, 23], ultra-small gold clusters [24, 25], rare-earth down-conversion nanoparticles (DCNPs) [26-28], and small organic dyes [29-44] have been discovered. It is worth noting that a novel small organic molecule H3-PEG2K exhibits excellent passive targeting ability and precise delineation of chemicallyinduced spontaneous breast cancer [45]. However, small-molecule NIR-II fluorophores are still in its fancy, and NIR-II fluorescence imaging of spontaneous breast tumors by the active targeting has not been reported yet.
Nucleolin, a receptor protein, traffics between membrane, cytoplasm, and nucleus [46]. Nucleolin is usually over-expressed on the membrane of breast cancer cells [47], indicating the potential of nucleolin to be a biomarker for breast cancer targeted imaging and therapy. The tumor-homing peptide F3, an N terminal fragment of human high mobility group protein 2 (HMGN2, formerly HMG-17) with 31-amino acid sequence (KDEPQRRSARL-SAKPAPPKPEPKPKKAPAKK), was first obtained from screening phage of mice bone marrow cells in vitro and from homing to HL-60 human leukemia tumor xenografts in vivo [48, 49]. F3 selectively targets cell-surface nucleolin in breast tumor cells and tumor endothelial cells. It also exhibits cell-penetrating properties with high cellular uptake in previous research. Therefore, it is desirable to designthe highlytumor-specific NIR-IIimaging probes based on F3 peptide.
Herein, we have rationally designed and synthesized a tumorhoming peptide-based NIR-II probe CH1055-F3 for targeted subcutaneous 4T1 xenografts and spontaneous breast tumor imaging. CH1055-F3 exhibited excellent specificity to 4T1 breast cancer and spontaneous breast cancer induced by the chemical reagent dimethylbenzanthracene (DMBA) [50]. To the best of our knowledge, it is the first time to develop a NIR-II probe to image both transplantable and spontaneous breast cancer through active targeting in the NIR-II window. Besides, image-guided tumor resection surgery for spontaneous breast tumor bearing rats was carried out in the NIR-II window, providing a promising method for tumor excision in clinic.
The tumor-homing peptide F3 has demonstrated a high specificity and affinity to nucleolin in breast tumor cells. F3 peptide was modified by an extra cysteine amino acid (Cys) in order to improve the reaction yield througha facile maleimide-thiol coupling reaction with a NIR-II dye CH1055-Mal. The NIR-II fluorophore CH1055 with four carboxyl groups was first amidated with maleimide to afford CH1055-Mal. Afterwards, the targeting peptide F3-Cys was conjugated to the intermediate CH1055-Mal based on a maleimide-thiol coupling reaction to obtain the monosubstituted CH1055-F3 in ~49% yield (Scheme 1). The structure was confirmed by MALDI-TOF-MS. The UV–vis-NIR absorption and fluorescence spectra of CH1055-F3 in water (Fig. 1A) indicated that the maximum absorption peak was ~726 nm and the maximum emission peak was 1020 nm with the large stokes shift of 294 nm. Meanwhile, CH1055-F3 exhibited excellent photostability in PBS for 60 min (Fig. 1B).
The 4T1 cell lines and HepG2 cell lines were applied to evaluate the potential cytotoxicity of CH1055-F3 by a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. As shown in Fig. 2A and Fig. S2 (Supporting information), no obvious toxicity was observed in both 4T1 and HepG2 cells and ~100% viability was shown at various dosages, suggesting the excellent biocompatibility of CH1055-F3 and great potential for in vivo bioimaging. CH1055-F3 was then injected into KM mice (5 μg/g) through the tail vein. The results demonstrated that CH1055-F3 was mainly distributed in the liver and kidneys (Fig. 2C). Ex vivo distribution results illustrated that the clearance route of this imaging agent was mainly via the hepatobiliary and renal systems. Through the quantitative analysis of major organs (Fig. 2D), the fluorescent signals of liver and kidneys were significantly higher than those of other organs (heart, lung and spleen). Meanwhile, the blood samples were collected from 0 to 10 h to measure the fluorescent intensity, and the half-life of CH1055-F3 in blood was calculated to be ~43.3 min based on the equation y = 7310.91 + 18878.66e-x/43.11) as shown in Fig. 2B, exhibiting the rapid whole-body elimination.
In vivo targeting experiments were first carried out in the subcutaneous 4T1 cells of tumor-bearing Balb/c mice. The mice (n = 3) were intravenously (i. v.) injected with 200 μL of PBS solution containing 0.2 mg CH1055-F3 through the tail vein when the tumor volumes reached at 400 ~ 800 mm3. The non-invasive NIR-II fluorescence imaging was performed on an InGaAs camera. As shown in Fig. 3, the 4T1 tumor was easily differentiated from the surrounding normal tissues. The intensity of fluorescence was increased from 2 h to 24 h, and reached the maximum at 10 h with a tumor signals/normal tissue signals (T/NT) value of 4.9 (Fig. 3 and Fig. S3 in Supporting information).
The transplanted, genetically engineered or environmentally caused such as chemically induced animal cancer models have been used to mimic different human cancer pathologies and address various research questions. The chemically induced spontaneous primary cancer models can simulate the originality, evolution and consequence of clinical cancer process, and are ideally used to investigate the etiology, prevention, diagnosis and treatment of cancer. Accordingly, a spontaneous DMBA-induced carcinoma model using Sprague Dawley (SD) female rats, comparable to the actual human breast tumors, was established to investigate the feasibility of CH1055-F3 for the tumor-homing targeted NIR-II imaging and image-guided surgery. SD rats were orally fed DMBA suspension in soya bean oil (20 mg/mL) at a dosage of 200 mg/kg in 10–15 weeks until the diameter of the primary tumors reached 10–20 mm. Subsequently, CH1055-F3 (2 mg in 1 mL PBS) was administrated into a DMBA-induced mammary carcinoma rat (n = 3) by intravenous injection and NIR-II fluorescence images of rat tumors were obtained at various time points (Fig. 4A). Three tumors on the SD rats were significantly visualized and delineated from the surrounding background tissues with the assistance of NIR-II imaging at 48 h. As shown in Fig. 4B, the process of the tumor resection was demonstrated, three tumors were successfully dissected and removed from the surrounding normal tissue. Specimen 1 with strong fluorescent NIR-II signals was stained with hematoxylin and eosin assessed (Figs. S5B and C in Supporting information). Histological analysis of specimen 1 has shown that the histological characteristics of normal tissues were almost not detected.
In summary, a NIR-II probe CH1055-F3 for tumor-specific imaging and imaging-guided surgery was successfully constructed via amidation and click reactions based on the dye CH1055 and F3 peptide. CH1055-F3 possessed excellent photo-stability, biocompatibility and tumor-specific ability, which showed excellent nucleolin-targeting performance in both transplantable and spontaneous breast cancer. Besides, image-guide surgery was successfully performed on the chemically DMBA-induced breast cancer rats. To the best of our knowledge, this is the first time that nucleolin-targeted NIR-II imaging for non-invasive tumor diagnosis of chemically induced spontaneous breast cancer and image-guided surgery in DMBA-induced mammary carcinoma rat was reported other than the xenograft model. This work provides a new approach to develop NIR-II probes to diagnose and excise tumor in clinic research. Moreover, this conception to design the NIR-II probes could enrich the filed for in vivo bioimaging, tumor targeting and various therapeutic applications in the future.
Declaration of competing interest
Less
The authors declare no conflict of interest.
Acknowledgments
Less
This work was partially supported by grants from the National Natural Science Foundation of China (Nos. 81773674, 21473041 and 81573383), Project First-Class Disciplines Development Supported by Chengdu University of Traditional Chinese Medicine (No. CZYJC1903), Natural Science Foundation of Hubei Province (Nos. 2017CFA024, 2016ACA126 and 2017CFB711), the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (No. 2019020701011429), 4 Shenzhen Science and Technology Research Grant (No. JCYJ20190808152019182), Tibet Autonomous Region Science and Technology Plan Project Key Project (No. XZ201901-GB-11), the Fundamental Research Funds for the Central Universities, and Health Commission of Hubei Province Scientific Research Project (Nos. WJ2019M177 and WJ2019M178).
Appendix A. Supplementary data
Less
Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.cclet.2020.04.030.
References
Less
[1]
H. Guo, J. Lu, H. Hathaway, et al., Bioconjugate Chem. 22(2011) 1682-1689.
[2]
O. Ginsburg, F. Bray, M.P. Coleman, et al., Lancet 389(2017) 847-860.
[3]
C.E. DeSantis, S.A. Fedewa, A. Goding Sauer, et al., CA-Cancer J. Clin. 66(2016) 31-42.
[4]
R. Bam, M. Laffey, K. Nottberg, et al., Bioconjugate Chem. 30(2019) 1677-1689.
[5]
C. Tang, Y. Du, Q. Liang, et al., Mol. Pharmaceut. 15(2018) 4702-4709.
[6]
C. Yan, L. Shi, Z. Guo, et al., Chin. Chem. Lett. 30(2019) 1849-1855.
[7]
X. Luo, J. Li, J. Zhao, et al., Chin. Chem. Lett. 30(2019) 839-846.
[8]
Y. Zhang, H. Teng, Y. Gao, et al., Chin. Chem. Lett. (2020), doi:http://dx.doi.org/10.1016/j.cclet.2020.03.020.
[9]
D. Shi, S. Chen, B. Dong, et al., Chem. Sci. 10(2019) 3715-3722.
[10]
L. Li, Y. Chen, W. Chen, et al., Chin. Chem. Lett. 30(2019) 1689-1703.
[11]
C. Li, Q. Wang, ACS Nano 12(2018) 9654-9659.
[12]
L. Tu, Y. Xu, Q. Ouyang, et al., Chin. Chem. Lett. 30(2019) 1731-1737.
[13]
C. Sun, B. Li, M. Zhao, et al., J. Am. Chem. Soc. 141(2019) 19221-19225.
[14]
Y. Li, Y. Liu, Q. Li, et al., Chem. Sci. 11(2020) 2621-2626.
[15]
Q. Li, Q. Ding, Y. Li, et al., Chem. Commun. 56(2020) 3289-3292.
[16]
Y. Li, Z. Cai, J. Qian, et al., Nat. Commun. 11(2020) 1255.
[17]
X. Hao, C. Li, Y. Zhang, et al., Adv. Mater. 30(2018) 1804437.
[18]
H. He, Y. Lin, Z. Tian, et al., Small 14(2018) 1703296.
[19]
C. Li, F. Li, Y. Zhang, et al., ACS Nano 9(2015) 12255-12263.
[20]
C. Li, Y. Zhang, M. Wang, et al., Biomaterials 35(2014) 393-400.
[21]
C. Zhu, G. Chen, Z. Tian, et al., Small 13(2017) 1602309.
[22]
G. Hong, J.C. Lee, J.T. Robinson, et al., Nat. Med. 18(2012) 1841-1846.
[23]
G. Hong, S. Diao, J. Chang, et al., Nat. Photonics 8(2014) 723-730.
[24]
H. Liu, G. Hong, Z. Luo, et al., Adv. Mater. 31(2019) 1901015.
[25]
Y. Chen, D.M. Montana, H. Wei, et al., Nano Lett. 17(2017) 6330-6334.
[26]
Y. Fan, P. Wang, Y. Lu, et al., Nat. Nanotechnol. 13(2018) 941-946.
[27]
P. Wang, Y. Fan, L. Lu, et al., Nat. Commun. 9(2018) 2898.
[28]
Y. Zhong, Z. Ma, S. Zhu, et al., Nat. Commun. 8(2017) 737.
[29]
B. Ding, Y. Xiao, H. Zhou, et al., J. Med. Chem. 62(2019) 2049-2059.
[30]
X. Zeng, Y. Xiao, J. Lin, et al., Adv. Healthcare Mater. 7(2018) 1800589.
[31]
Y. Sun, M. Ding, X. Zeng, et al., Chem. Sci. 8(2017) 3489-3493.
[32]
J. Lin, X. Zeng, Y. Xiao, et al., Chem. Sci. 10(2019) 1219-1226.
[33]
A.L. Antaris, H. Chen, K. Cheng, et al., Nat. Mater. 15(2016) 235-242.
[34]
B. Li, L. Lu, M. Zhao, et al., Angew. Chem. Int. Ed. 57(2018) 7483-7487.
[35]
J. Yang, Q. Xie, H. Zhou, et al., J. Proteome Res. 17(2018) 2428-2439.
[36]
H. Zhou, H. Yang, L. Tang, et al., J. Mater. Chem. C 7(2019) 9448-9454.
[37]
Y. Sun, C. Qu, H. Chen, et al., Chem. Sci. 7(2016) 6203-6207.
[38]
H. Zhou, W. Yi, A. Li, et al., Adv. Healthcare Mater. 9(2019) 1901224.
[39]
H. Zhou, Y. Xiao, X. Hong, Chin. Chem. Lett. 29(2018) 1425-1428.
[40]
A.L. Antaris, H. Chen, S. Diao, et al., Nat. Commun. 8(2017) 15269.
[41]
Y. Sun, X. Zeng, Y. Xiao, et al., Chem. Sci. 9(2018) 2092-2097.
[42]
C. Qu, Y. Xiao, H. Zhou, et al., Adv. Opt. Mater. 7(2019) 1900229.
[43]
J. Lin, Q. Li, X. Zeng, et al., Sci. China Chem. 63(2020) 766-770.
[44]
J. Yang, X. Hong, Sci. China Chem. 62(2019) 7-8.
[45]
X. Zeng, L. Xie, D. Chen, et al., Chem. Commun. 55(2019) 14287-14290.
[46]
X. Fu, C. Liang, F. Li, et al., Int. J. Mol. Sci. 19(2018) 1445.
[47]
B. Cornelissen, A. Waller, C. Target, et al., Ejnmmi Res. 2(2012) 9.
[48]
K. Porkka, P. Laakkonen, J.A. Hoffman, et al., Proc. Natl. Acad. Sci. U. S. A. 99(2002) 7444-7449.
[49]
Y. Zhang, M. Yang, J. Park, et al., Small 5(2009) 1990-1996.
[50]
Y. Liu, T. Yin, Y. Feng, et al., Quant. Imag. Med. Surg. 5(2015) 708-729.
Appendix
Less
Year 2020 volume 31 Issue 6
PDF
45
24
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2020.04.030
  • Receive Date：2020-03-04
  • Online Date：2026-01-31
  • Published：2020-06-15
Article Data
Affiliations
History
  • Received：2020-03-04
  • Revised：2020-04-08
  • Accepted：2020-04-16
Affiliations
    a Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
    b Key Laboratory of Combinatorial Biosynthesis and Drug Discovery(MOE), Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Shenzhen Institute of Wuhan University, Shenzhen 518057, China
    c College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lasa 850000, China
    d Jiangxi Key Laboratory of Organo-Pharmaceutical Chemistry, Chemistry and Chemical Engineering College, Gannan Normal University, Ganzhou 341000, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2020.04.030
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House